Integrin subunit as surrogate marker for MS relapse

The anti-α4-integrin monoclonal antibody natalizumab (Tysabri) is effective in most patients in treating multiple sclerosis (MS), but a percentage of people develop infusion reactions or stop responding because they develop neutralizing antibodies, and some people may have neutralizing antibodies without symptoms. Expression of CD49d, a subunit of α4-integrin on peripheral blood mononuclear cells (PBMCs) fall with successful treatment. French researchers looked at a group of people with relapsing-remitting MS, and found that levels of CD49d expression rise early or do not fall in patients with neutralizing antibodies--this could be used as a surrogate biomarker of natalizumab efficacy. Abstract

Suggested Articles

Johnson & Johnson Vision announced that the worldwide president of its surgical business, Tom Frinzi, plans to retire at the end of this year.

Philips looked back on 15 years of data from one of its telehealth-equipped intensive care units, where centralizing operations reduced mortality.

Sanofi will look to pull back from its three-year-old relationship with Verily and their virtual diabetes clinic, Onduo.